首页> 外国专利> Thrombin inhibitor (N)-arylsulphonyl-(L)-arginine amide derivs. - prepd. e.g. by reacting (L)-arginine amide cpds. with arylsulphonyl halides

Thrombin inhibitor (N)-arylsulphonyl-(L)-arginine amide derivs. - prepd. e.g. by reacting (L)-arginine amide cpds. with arylsulphonyl halides

机译:凝血酶抑制剂(N)-芳基磺酰基-(L)-精氨酸酰胺衍生。 -准备例如使(L)-精氨酸酰胺cpds反应。与芳基磺酰卤化物

摘要

New N2-arylsulphonyl-L-argininamide derivs are cpds. of the formula HN=C(NH2)-NH-CH2CH2CH(COR)-NH-SO2-Ar (I) and their salts with acids or bases. In (I), R is NR1-(CH2)n-COOR2, -NR3-CHR4-(CH2)m-COOR5, or (Ia), (Ib), (Ic) or (Id). R1 and R3 are 2-10C alkyl, 3-10C alkenyl, or alkynyl, 2-10C alkoxy- alkyl, 2-10C alkylthio-alkyl, 2-10C alkylsulphinylalkyl, 1-10C hydroxyalkyl, 2-10C carboxyalkyl, 3-10C alkoxy-carbonylalkyl, 3-10C alkylcarbonyl, 1-10C haloalkyl, 7-15C aralkyl, 8-15, alpha-carboxyaralkyl, 3-10C cycloalkyl, 4-10C cycloalkyl, 4-10C cycloalkylalkyl, furfuryl, opt. substd. tetrahydrofurfuryl 3-furylmethyl, opt. substd. tetrahydro-3-furylmethyl tetrahydro-2(3- or 4-)-pyranylmethyl opt. substd. 1, 4-dioxa-2-cyclohexylmethyl or opt. 2- or 3-thenyl or tetrahydro-2- or 3-thenyl. R2 is H, 1-10C alkyl, 6-10C aryl, 7-12C aralkyl or 5-indanyl. n is 1,2 or 3. R4 is 1-10C alkyl, COOH, 2-10C alkoxycarbonyl, opt. substd. phenyl 7-12C aralkyl, or benzyl nuclear-substd. by 1-5C alkyl or alkoxy. R5 is H, 1-10C alkyl, 6-10C aryl, 7-12C aralkyl or 5-indanyl. m is 0, 1 or 2. R6 is -COOR8 in the 2- or 3- position, R8 being H, 1-10C alkyl, 6-10C aryl, 7-12C aralkyl or 5-indanyl R7, which is in the 2-, 3- 5- and/or 6-position is H, 1-10C alkyl, phenyl, 1-5C alkoxy or COOH. p is 1-3. The (Ib) is opt. substd. by 1 1-5C alkyl and/or alkoxy residue; R9 is H, 1-10C alkyl, 6-10C aryl, 7-12C aralkyl or 5-indanyl and r is 1,2,3 or 4. R10 is H, 1-10C alkyl, 6-10C aryl, 7-12C aralkyl or 5-indanyl, Z is O, S or SO. q is 0 or 1. R11 is H, 1-10C alkyl, 6-10C aryl, 7-12C aralkyl or 5-indanyl. i is 0,1 or 2 and j is 0,1 or 2 i + j being 1 or 2. Ar is opt. substd. naphthyl; opt. substd. 5,6,7,8-tetrahydronaphthyl 1-5C opt. substd. 7-12C aralkyl; or an oxygen contg. fused ring heterocyclic cpd. (I) are highly specific thrombin inhibitors. They are suitable for the prophylaxis and therapy of thromboses. Their toxicity is low. (I) are also useful as inhibitors of thrombocyte aggregation. Specific cpds. (I) include N2-(6, 7-dimethoxy-2-naphthylsulphonyl) L-arginyl-N-butyl-glycine. In an example, this spd. is prepd. in 4 stages from L-arginine.
机译:新的N2-芳基磺酰基-L-精氨酰胺衍生物是cpds。式HN = C(NH 2)-NH-CH 2 CH 2 CH(COR)-NH-SO 2 -Ar(I)及其与酸或碱的盐。在(I)中,R为NR 1-(CH 2)n -COOR 2,-NR 3 -CHR 4-(CH 2)m -COOR 5或(Ia),(Ib),(Ic)或(Id)。 R1和R3是2-10C烷基,3-10C烯基或炔基,2-10C烷氧基-烷基,2-10C烷硫基-烷基,2-10C烷基亚磺酰基烷基,1-10C羟烷基,2-10C羧烷基,3-10C烷氧基-羰基烷基,3-10C烷基羰基,1-10C卤代烷基,7-15C芳烷基,8-15,α-羧基芳烷基,3-10C环烷基,4-10C环烷基,4-10C环烷基烷基,糠基。取代四氢糠基3-糠基甲基取代四氢-3-呋喃基甲基四氢-2(3-或4-)-吡喃基甲基opt。取代1,4-dioxa-2-cyclohexylmethyl或opt。 2-或3-乙烯基或四氢-2-或3-乙烯基。 R 2是H,1-10C烷基,6-10C芳基,7-12C芳烷基或5-茚满基。 n为1,2或3。R4为1-10C烷基,COOH,2-10C烷氧羰基(可选)。取代苯基7-12C芳烷基或苄基核基。 1-5C烷基或烷氧基。 R5是H,1-10C烷基,6-10C芳基,7-12C芳烷基或5-茚满基。 m为0、1或2。R6为2-或3-位的-COOR8,R8为H,1-10C烷基,6-10C芳基,7-12C芳烷基或5-茚满基R7,位于2位3-5,和/或6-位是H,1-10C烷基,苯基,1-5C烷氧基或COOH。 p是1-3。 (Ib)是可选的。取代在1 1-5C烷基和/或烷氧基残基上; R 9为H,1-10C烷基,6-10C芳基,7-12C芳烷基或5-茚满基,且r为1,2,3或4。R10为H,1-10C烷基,6-10C芳基,7-12C芳烷基或5-茚满基,Z为O,S或SO。 q为0或1。R 11为H,1-10C烷基,6-10C芳基,7-12C芳烷基或5-茚满基。 i为0,1或2,j为0,1或2 i + j为1或2。Ar为opt。取代萘基选择。取代5,6,7,8-四氢萘1-5C最佳。取代7-12C芳烷基;或氧气接触稠环杂环cpd。 (I)是高度特异性的凝血酶抑制剂。它们适用于血栓形成的预防和治疗。它们的毒性低。 (I)也可用作血小板聚集的抑制剂。特定的cpds。 (I)包括N 2-(6,7-二甲氧基-2-萘磺酰基)L-精氨酸基-N-丁基-甘氨酸。在示例中,此spd。准备好了。从L-精氨酸分4个阶段

著录项

  • 公开/公告号FR2334349B1

    专利类型

  • 公开/公告日1983-07-22

    原文格式PDF

  • 申请/专利权人 MITSUBISHI CHEMICAL IND LTD;

    申请/专利号FR19760037163

  • 发明设计人

    申请日1976-12-09

  • 分类号A61K37/24;C07C143/78;C07D315/00;C07D325/00;C07D405/12;C07D227/08;C07D269/00;C07D283/00;

  • 国家 FR

  • 入库时间 2022-08-22 10:02:48

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号